Home › Funds › Global X › Global X Aging Population ETF
Fund family: Global X · Filed by Global X Funds (CIK 1432353) · SEC series S000054162
Ticker: AGNG (C000170216)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 999 with, 20 against, 5 abstentions (not counted as with management); 177 items carried no recommendation; 16 split votes are in neither count. Shareholder proposals: 21 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Global X’s manager page (125,623 ballot items across 92 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Global X | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 90.4% | 842 | 91.0% | 107,427 |
| Backed environmental and social shareholder proposals at US companies | n/a | 4 | 21.0% | 2,383 |
Each ballot item this fund voted is set against the votes of the other Global X funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Global X funds on all 243 items where a comparison was possible.
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 605 | 1 |
| Corporate Governance | 202 | 9 |
| Compensation | 126 | 3 |
| Capital Structure | 112 | 0 |
| Audit-related | 81 | 2 |
| Say-on-Pay | 50 | 0 |
| Shareholder Rights and Defenses | 16 | 1 |
| Other Social Issues | 5 | 2 |
| Extraordinary Transactions | 3 | 0 |
| Diversity, Equity, and Inclusion | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| agilon health, inc. | March 17, 2026 | $4M | 2 | 0 |
| Eli Lilly and Company | May 4, 2026 | $4M | 10 | 2 |
| Merck & Co., Inc. | May 26, 2026 | $4M | 18 | 3 |
| Johnson & Johnson | April 23, 2026 | $4M | 15 | 1 |
| Welltower Inc. | May 21, 2026 | $4M | 11 | 0 |
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $3M | 7 | 0 |
| AbbVie Inc. | May 8, 2026 | $3M | 8 | 1 |
| Amgen Inc. | May 19, 2026 | $3M | 15 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | For | Against |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | For | Against |
| May 8, 2026 | AbbVie Inc. | Stockholder proposal - to adopt a policy to require an independent chair Shareholder proposal | For | Against |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | For | Against |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | For | Against |
| May 22, 2026 | Zimmer Biomet Holdings, Inc. | Shareholder proposal on Independent Board Chairman. Shareholder proposal | For | Against |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | For | Against |
| March 31, 2026 | Dentium Co.,Ltd. | Establishment of an Evaluation and Compensation Committee (Shareholder Proposal) Shareholder proposal | For | Against |
| March 31, 2026 | Dentium Co.,Ltd. | Change the Name of Outside Directors and Expand/Guarantee Their Ratio (Shareholder Proposal) Shareholder proposal | For | Against |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
1,202 ballot items at 94 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Global X Aging Population ETF (AGNG) voted at 94 shareholder meetings of 86 companies, on 1,202 ballot items in all. Where management made a recommendation, the fund followed it on 97.6% of the items and voted against it 20 times. Its most frequent area of disagreement was corporate governance (9 of its votes against management). It voted on 33 shareholder proposals. It voted FOR the board's own proposals less often than Global X's funds as a whole (90.4% against 91.0%). It voted the same way as most Global X funds on every item where a comparison was possible. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Global X’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.